TBPB

TBPB (tert-butyl peroxybenzoate) is a highly selective, blood-brain-permeable M1 mAChR allosteric agonist (EC₅₀=289 nM) with anti-schizophrenia and anti-inflammatory activities. TBPB can enhance the sensitivity of M1 receptors to acetylcholine, activate downstream signaling pathways, and inhibit the release of pro-inflammatory cytokines (TNF-α, IL-6). TBPB can regulate the processing of amyloid and can be used in the study of neurodegenerative diseases (such as Alzheimer's disease) and inflammation-related diseases (such as sepsis)^[1][2][3]. In Vivo:TBPB (60 mg/kg; subcutaneous injection; single dose; 2 h before sepsis induction) significantly reduces mortality in E. coli-induced murine sepsis model, with 20% and 23.2% decreases in 4- and 24-hour mortality, while inhibiting TNF-α, IL-1β, and IL-6 levels^[3].